/ Active, not recruitingPhase 2 PHASE II CLINICAL TRIAL OF IMMUNOTHERAPY WITH AN ALLOGENEIC B7.1/HLA-A1 TRANSFECTED TUMOR CELL VACCINE (PT 107) IN PATIENTS WITH STAGES IIIB/IV NON-SMALL CELL LUNG CANCER THAT HAVE COMPLETED FIRST LINE CHEMOTHERAPY
100 Clinical Results associated with Pique Therapeutics, Inc.
0 Patents (Medical) associated with Pique Therapeutics, Inc.
100 Deals associated with Pique Therapeutics, Inc.
100 Translational Medicine associated with Pique Therapeutics, Inc.